Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction
About The Study: In the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF), finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, had similar tolerability in women and men.
Corresponding Author: To contact the corresponding author, John J. V. McMurray, MD, email john.mcmurray@glasgow.ac.uk.
To ...








